Zafgen discontinues beloranib By: MarketMinute.com Stock News July 20, 2016 at 19:04 PM EDT Zafgen Inc. (Nasdaq: ZFGN) will discontinue the development of its obesity treatment beloranib and cut its workforce by 34% sending the stock price plummeting $3.51 to close at $3.24. Related Stocks: Zafgen Inc